A review explains why one aging target has a stronger effect in worms than in mice
A review explains why one aging target has a stronger effect in worms than in mice
On July 12, Mechanisms of Ageing and Development published a review examining why interventions against aging often produce large effects in simple animals but much smaller effects in mammals. The authors brought together evidence from worms, fruit flies, and rodents. They propose that the reason may lie in communication between tissues, hormonal signaling, and feedback loops that change the response of the whole organism.
Geroscience has long recognized this difference. A mutation in the signaling pathway through which insulin and IGF-1 regulate growth and metabolism can double the lifespan of the worm C. elegans. Rapamycin, one of the most extensively studied drugs for aging, produced a much smaller effect in mice. When treatment began at 600 days of age, the age at 90% mortality increased by 14% in females and 9% in males.
In worms, a small set of pathways jointly regulates nutrition, stress responses, reproduction, and cellular repair. Mammalian bodies distribute these functions across many tissues. The liver, immune system, adipose tissue, muscles, gut bacteria, and hormonal signals continuously alter one another's state. The authors define organismal complexity as the number of these connections and reserves, not as body size or genome length.
The authors call the influence of a single target pathway leverage. The more an organism can change its lifespan by altering one pathway, the greater that pathway's leverage. This effect is opposed by systemic buffering. Backup genes, parallel signaling pathways, and feedback between organs return the organism to a functional state after an intervention.
Under this model, a drug may precisely alter mTOR, a cellular regulator of growth and resource use, or another established pathway, but several responses can counter its effect at once. Another tissue compensates for the change. A hormone alters metabolism. Gut bacteria change the molecule's availability. The organism delivers and processes the drug in its own way. As the number of these connections increases, it becomes harder for a single target to change the lifespan of the whole body.
Research in mice already provides an example of this approach. The combination of rapamycin and trametinib increased median lifespan by approximately 30%, more than either drug alone. The new review raises a further question: which combinations should be selected after accounting for how different tissues respond to each target?
The paper does not measure “buffering” with a single instrument, nor does it establish a limit on human lifespan. It is a qualitative review, not an experiment with a new therapy. Its proposal can be tested by comparing the compensatory responses activated in different tissues after an intervention and determining whether combinations of interventions enhance one another's effects.
The next generation of studies should map which tissue cancels a beneficial effect, which signal it uses to do so, and the order in which interventions should be applied so that compensation by other organs does not eliminate the result.